secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0000950170-23-024290
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay reports complete dose escalation data for RLY-4008; 73% ORR in FGFRi-naïve CCA at pivotal dose
--------------------------------------------------------------------------------

- Among FGFRi-naïve FGFR2-fusion CCA patients at or above 70mg QD (n=11): 73% ORR, median DoR 11.2 months.
- Patients at lower doses (n=14): 36% ORR; median DoR 5.6 months.
- Safety consistent with prior data: no Grade 4/5 AEs; off-target hyperphosphatemia/diarrhea clinically insignificant.
- Data cut-off Jan 30, 2023; presentation at ASCO on June 4, 2023.
- Pivotal cohort enrollment completion and initial non-CCA expansion data expected in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/0000950170-23-024290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/rlay-20230525.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer